Clinical Trials Logo

Filter by:
NCT ID: NCT06222060 Recruiting - Clinical trials for Shaken Baby Syndrome

Evaluation of Young Parents' Knowledge of Shaken Baby Syndrome in Maternity Wards

Start date: May 2, 2023
Phase:
Study type: Observational

As part of everyday clinical practice, messages about preventing Shaken Baby Syndrome are delivered to young parents in maternity wards. The modality of these messages changes regularly. For example, in the near future, the messages will be delivered by video in addition to the usual practice. The investigators are setting up a prospective observational cohort study in order to evaluate and then monitor the state of knowledge of young parents on shaken baby syndrome.

NCT ID: NCT06222034 Recruiting - Clinical trials for Juvenile Idiopathic Arthritis

Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)

Start date: May 13, 2024
Phase: Phase 1
Study type: Interventional

A Study to evaluate the pharmacokinetics, safety, and tolerability in paediatric population for treating juvenile idiopathic arthritis (JIA).

NCT ID: NCT06221969 Recruiting - Type 2 Diabetes Clinical Trials

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Start date: January 16, 2024
Phase: Phase 3
Study type: Interventional

This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either drug. For each participant, the study will last for up to one and a half years.

NCT ID: NCT06220669 Recruiting - Multiple Sclerosis Clinical Trials

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

Start date: March 19, 2024
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.

NCT ID: NCT06220201 Recruiting - Multiple Sclerosis Clinical Trials

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis or Progressive Forms of Multiple Sclerosis

Start date: March 28, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS) or Progressive Forms of Multiple Sclerosis (PMS).

NCT ID: NCT06219798 Recruiting - Clinical trials for Kidney Function Issue

Evaluation of a Pathway on the Evolution of Renal Function in Patients With Advanced Chronic Kidney Disease

EPSER
Start date: April 9, 2024
Phase:
Study type: Observational

The number of incident and prevalent patients with end stage renal disease on dialysis treatment is increasing in France and worldwide. A quarter of dialysis patients are initiating dialysis urgently through central venous catheters and the number of patients registered in the waiting list for renal transplantation before dialysis initiation is very low. This is also reflected in the very low number of pre-emptive renal transplantations. In order to reduce the number of dialysis patients, the French state has induced a national program proposing a multidisciplinary care pathway including the nephrology visits and at least one consultation with a dietitian and a specialist renal nurse in all patients with Chronic Kidney Disease stage 4 and 5. The aim of this single-center retrospective study is to evaluate the influence of the complete, partial or no participation in this program on the evolution of renal function and clinicobiological parameters in this group of patients.

NCT ID: NCT06219187 Recruiting - Breast Cancer Clinical Trials

Male breAsT cAncer preDisposition Factor

MATADOR
Start date: February 8, 2024
Phase:
Study type: Observational

This is a non-interventional, prospective, single-center study designed to collect and describe environmental and psychosocial data from patients with a history of male breast cancer (MBC) referenced in the IUCT-O regional database. The study will be conducted on a population of 110 to 150 patients.

NCT ID: NCT06219135 Recruiting - Sepsis Clinical Trials

Evaluation of the Performance of the IDBIORIV Method in Pathogen Identification and Antibiotic Susceptibility Testing in Patients With Sepsis

IDBIORIV
Start date: March 21, 2024
Phase:
Study type: Observational

Sepsis is a disruption of homeostasis in the human body in response to bloodstream infection and is associated with a high risk of mortality. Worldwide, sepsis is affecting approximately 30 million people and resulting in six million deaths. Blood culture is a specific blood sample used to identifying microbial agent (bacterium or yeast) and determine the sensitivity of these microorganisms to antibiotics and antifungals. Any delay in identifying the microorganism and/or determining the AST (antibiotic susceptibility testing) has a direct impact on the administration of appropriate antibiotic treatment and, consequently, on mortality of the patient. The faster the diagnosis, the faster the antibiotic treatment will be adapted, the higher the survival rate/probability of patients, and the lower the ecological impact. In routine, clinical microbiology laboratories currently use 2 automatized techniques: MALDI-TOF MS® for microorganisms identification and VITEK2® method for AST determination. Based on a proteomic approach, the IDBIORIV method is a rapid method (90 minutes) in comparison of current methods (24/48 hours) able to identifying a large panel of 113 pathogens and determine the antibiotic resistance profile of 49 species for 4 classes of antibiotics (Beta-lactams, Aminosides, Glycopeptides, Colistin). The main objective of this study is to evaluate the performance of the IDBIORIV method in pathogen identification and antibiotic susceptibility testing in comparison with current methods of analysis of positive blood cultures used at the microbiology laboratory of the Hospices Civils de Lyon, in a real clinical situation, over a 2-year period.

NCT ID: NCT06218576 Recruiting - Clinical trials for Acute Cerebral and Cerebellar Cortical Microinfarctions (CMI)

Sensitivity Comparison of Follow-up MRI Between Acute Cerebral and Cerebellar Cortical Microinfarctions ( CMI )Microinfarctions

CMI
Start date: February 15, 2024
Phase:
Study type: Observational

Cerebral cortical microinfarctions (CMI) are frequently observed on MRI and histology studies, especially in elderly patients and in patients with cognitive dysfunction. The majority of these studies analysed chronic cerebral CMI lesions. The few studies reporting on temporal dynamics of MRI signal of acute cerebral CMI showed very low sensibility for persisting signal changes on follow-up MRI on standard MRI sequences. A retrospective study, analysing follow-up 3T MRI in 25 patients with acute cerebral CMI (defined as ≤10 mm on DWI), showed a chronic cerebral CMI detection rate of only 16% on T2-weighted and 5% on FLAIR imaging after a mean follow-up period of 33 months (with a very wide range of 0.5-142 months). Another 3T MRI study including seven patients showed disappearance of all acute cerebral very small-sized CMI (defined as <5 mm size on initial DWI) on all follow-up MRI sequences (T1- and T2-weighted and FLAIR imaging, performed after one month). Recently, it has been shown that chronic relatively small (<20 mm) cerebellar cortical infarctions (based on diffusion-weighted imaging) were frequently observed in acute stroke patients, especially in case of cardioembolic stroke (with chronic small cerebellar cortical infarctions observed in 32% of cases). The high prevalence of these chronic small cerebellar cortical infarctions suggest a possible higher detection rate of chronic small-sized infarction in the cerebellum compared to the supratentorial brain.

NCT ID: NCT06218563 Recruiting - Healthy Clinical Trials

Study of Cerebral Activation by fNIRS During Vibration-induced Illusion of Movement in Healthy and Stroke Participants.

VIBRANIRS
Start date: January 10, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the cerebral activation of healthy and stroke participants in 4 or 2 different conditions (repeated 2 times) of vibration-induced illusion of movement respectively, resulting in 8 or 4 vibration blocks with 3 vibrations per block. The frequency of the vibration being 80 Hz. Healthy participants: - Right arm, eyes opened - Right arm, eyes closed - Left arm, eyes opened - Left arm, eyes closed Stroke participants: - Deficient side, eyes opened - Deficient side, eyes closed The aim is to compare the subjective sensation of movement score and cerebral activations of healthy/stroke participants depending on the condition.